# Product Brief: ClinicalTrials.gov as a Data Source for CluePoints

**Date:** 2026-03-24
**Author:** Product Team
**Status:** Draft — for discussion

---

## Executive Summary

ClinicalTrials.gov is the world's largest publicly accessible clinical trial registry, maintained by the U.S. National Library of Medicine (NLM). It contains structured, machine-readable protocol and results data on over 500,000 studies. For CluePoints, it represents a unique external intelligence layer: a dataset that is continuously updated throughout the trial lifecycle, carries regulatory weight, and is systematically underused by RBQM-focused vendors.

This brief maps what the registry contains, when and how sponsors contribute data, how reliable it is, what the legal obligations are, how it fits in the broader global registry ecosystem, and how CluePoints' competitors are already leveraging it — to frame the opportunity for our own product strategy.

---

## 1. What ClinicalTrials.gov Contains

Every registered study record has up to three sections: **Protocol**, **Results**, and **Documents**.

### 1.1 Protocol Section (Registration Data)

| Category | Key Fields |
|---|---|
| **Identification** | NCT number, sponsor protocol ID, brief title, official title, secondary IDs |
| **Status** | Overall recruitment status, individual site status, study start date, primary completion date (anticipated vs. actual), study completion date |
| **Design** | Study type (interventional / observational), phase, primary purpose, allocation (randomized / non-randomized), masking/blinding, interventional model |
| **Arms & Interventions** | Number of arms, arm labels, arm type (experimental / comparator / placebo), intervention names, drug generic names, dosing |
| **Endpoints** | Primary and secondary outcome measures, time frames for measurement |
| **Eligibility** | Inclusion/exclusion criteria, age range, sex, whether healthy volunteers are accepted |
| **Enrollment** | Target enrollment count; updated to actual count at completion |
| **Sites & Contacts** | Site names, city, country, per-site recruitment status, central contact details |
| **Sponsor** | Sponsor name, responsible party (sponsor or PI), affiliation |
| **Oversight** | FDA-regulated drug/device flags, IND/IDE numbers, U.S. and non-U.S. oversight authority |

### 1.2 Results Section (Post-Completion Data)

Submitted no later than 12 months after the primary completion date. Contains:

- **Participant flow:** Enrollment, allocation, and dropout counts by arm
- **Baseline characteristics:** Demographics and key baseline measures by arm
- **Outcome measure data:** Tabular results for each primary and secondary endpoint, with statistical analyses
- **Adverse events:** Serious adverse events (SAEs) and other adverse events by type, frequency, and arm
- **Protocol upload:** PDF version of the full protocol document

### 1.3 What Is Notably Absent

ClinicalTrials.gov does not contain:
- Individual patient-level data
- Site monitoring findings or SDV/SDR outcomes
- Query logs or data quality metrics
- EDC or CTMS operational data
- Actual source documents

---

## 2. When Sponsors Enter Data Across the Trial Lifecycle

Data is contributed at specific legally mandated moments, not continuously streamed. Understanding this cadence is critical for assessing data freshness.

```
Trial Lifecycle → ClinicalTrials.gov Data Events

[Study Design]
      │
      ▼
[First Patient In] ──────────────────────── Registration due within 21 days
      │                                      (ICMJE: before first patient)
      │
[During the Trial] ──────────────────────── Updates within 30 days of:
      │                                       • Protocol amendments
      │                                       • Enrollment status changes
      │                                       • Site additions/removals
      │                                       • Completion date changes
      │                                      At minimum: every 12 months
      │
[Primary Completion Date] ───────────────── PCD updated Anticipated → Actual
      │                                      within 30 days
      │
[~12 Months Post-PCD] ───────────────────── Results posted (mandatory)
      │                                      (up to +24 months if unapproved product)
      │
[Study Completion Date]
```

**Practical implication:** ClinicalTrials.gov data is **retrospective and episodic**, not real-time. Protocol data can be stale by up to 12 months between mandatory updates. Results data lags real-world completion by 12–36 months depending on product approval status.

---

## 3. How Often Is Information Updated?

| Update Type | Required Frequency |
|---|---|
| Any protocol change (status, sites, dates, amendments) | Within 30 days of change |
| Device clearance change | Within 15 days |
| Routine review with no changes | At minimum every 12 months |
| Primary completion date (Anticipated → Actual) | Within 30 days |
| Results posting | Within 12 months of primary completion |

In practice, update cadence is uneven. Many sponsors — particularly academic institutions — update late or not at all. A 2024 analysis found overall 12-month results compliance at only **37.2%** across all sponsor types.

---

## 4. How Reliable Is the Data?

### 4.1 Strengths

- **Structured and machine-readable:** The ClinicalTrials.gov API (v2.0) and the AACT relational database (updated daily) make the data highly accessible for systematic analysis.
- **Regulatory standing:** Information carries legal weight. False or misleading entries are subject to civil penalties of up to $13,237/day.
- **Longitudinal history:** Records capture the evolution of a trial over time, including amendments and status changes.
- **Scale:** 500,000+ studies globally, representing the largest single source of clinical trial metadata available publicly.

### 4.2 Known Limitations

A 2024 study in the *Journal of Clinical Epidemiology* systematically assessed data quality across ClinicalTrials.gov and identified four recurring failure modes:

| Issue | Description |
|---|---|
| **Incompleteness** | Required fields left blank or insufficiently populated |
| **Inaccuracy** | Dates, enrollment counts, and status fields that do not match the real state of the trial |
| **Inconsistency** | Data that contradicts information in companion registries (e.g., EUCTR) or published literature |
| **Timeliness deficits** | Updates posted late or not at all, especially for completion dates and results |

### 4.3 Sponsor Compliance Rates (2017–2024)

| Sponsor Type | 12-Month Results Compliance |
|---|---|
| Industry | 73.7% |
| NIH-funded | 71.0% |
| Academic / AMC | 25.5% |
| **Overall average** | **37.2%** |

Industry sponsors — who represent the majority of CluePoints' customers — are substantially more compliant than academic centers. However, even at 73.7%, meaningful data gaps remain.

**Practical guidance:** ClinicalTrials.gov data should be treated as a **signal source, not ground truth**. It is most reliable for structural facts (design, phase, indication, sponsor) and least reliable for real-time operational status.

---

## 5. Who Is Legally Required to Register?

### 5.1 Mandatory Registration (FDAAA 801 + 42 CFR Part 11)

The Food and Drug Administration Amendments Act of 2007 (FDAAA) and the 2017 Final Rule (42 CFR Part 11) mandate registration for **Applicable Clinical Trials (ACTs)**. A study qualifies as an ACT if it:

- Is an **interventional study** of a drug, biologic, or device subject to FDA regulation; AND
- Meets at least one of:
  - Has one or more sites **in the United States**
  - Is conducted under an **IND or IDE**
  - Involves a drug, biologic, or device manufactured in the U.S.

**Specific scopes:**

| Product Type | Mandatory Phases |
|---|---|
| Drugs and biologics | Phase 2, 3, and 4 (Phase 1 excluded unless NIH-funded) |
| Medical devices | Prospective comparative studies; pediatric post-market surveillance per FDA order |
| Behavioral / other interventions | Only if NIH-funded (see below) |

> **Phase 1 drug trials are explicitly excluded** from FDAAA's mandatory registration requirement unless covered by separate NIH policy.

### 5.2 NIH Policy (Effective January 2017)

All clinical trials **funded in whole or in part by NIH** must be registered, regardless of phase, product type, or whether FDA-regulated. This extends the obligation to:
- Phase 1 trials
- Behavioral and social interventions
- Small feasibility device trials

### 5.3 ICMJE Publication Requirement

As of 2005, most top-tier medical journals (ICMJE members) require registration **prior to first enrollment** as a condition for publication. This is a practical forcing function that extends the obligation even to non-FDA, non-NIH studies where investigators seek to publish.

### 5.4 What Is Not Required

- Phase 1 industry-only drug/biologic trials (no U.S. sites, no IND)
- Purely observational studies (unless NIH-funded)
- Studies of non-FDA-regulated products outside of NIH funding
- Studies with no U.S. sites and no IND/IDE (although many register voluntarily for ICMJE compliance)

---

## 6. Global Clinical Trial Registry Ecosystem

ClinicalTrials.gov is the dominant registry but exists within a broader international infrastructure. Sponsors running global trials must navigate multiple registries.

### 6.1 WHO International Clinical Trials Registry Platform (ICTRP)

- **Type:** Meta-registry and search portal — not a registry itself
- **Role:** Aggregates data from 17 primary WHO-recognized registries, providing a single global search interface
- **Scale:** 689,793 trials indexed (as of 2020), exceeding ClinicalTrials.gov's ~362,500
- **Use:** Used by researchers, policymakers, and systematic reviewers for global trial discovery. Sponsors do not register directly here — they register in a primary registry that feeds ICTRP.

### 6.2 EU Clinical Trials Register (EUCTR / EudraCT)

- **Type:** Primary registry; regulatory database
- **Operator:** European Medicines Agency (EMA)
- **Scope:** All clinical trials conducted in the EU since May 2004
- **Obligation:** Mandatory for any trial with at least one EU member state site, regardless of sponsor nationality
- **Unique feature:** Results posting compliance has been faster than ClinicalTrials.gov — median time to results on EUCTR was 1,142 days vs. 3,321 days on ClinicalTrials.gov (for matched records)
- **Evolution:** Being migrated to the new **CTIS (Clinical Trials Information System)** under EU CTR Regulation 536/2014, which went live in January 2023

### 6.3 ISRCTN Registry

- **Type:** Primary WHO-recognized registry
- **Operator:** BioMed Central (Springer Nature)
- **Scope:** International; accepts interventional and observational studies, all health areas
- **Obligation:** Not legally mandated but widely used for ICMJE journal compliance, particularly in the UK and Europe
- **Unique feature:** Expert editorial curation of records before publication

### 6.4 Other Notable Regional Registries

| Registry | Region | Authority |
|---|---|---|
| CTRI | India | ICMR |
| ChiCTR | China | Chinese MoH |
| IRCT | Iran | Ministry of Health |
| ANZCTR | Australia / NZ | NHMRC |
| JRCT | Japan | Integrated registry |

### 6.5 Multi-Registry Reality for Global Sponsors

A Phase 3 trial run by a large pharma company with sites in the US, EU, and India will typically appear in **ClinicalTrials.gov + EUCTR/CTIS + CTRI** — sometimes with minor inconsistencies between records. The ICTRP links these via a Universal Trial Number (UTN) but deduplication remains imperfect (~0.5% of ICTRP records are hidden duplicates, 82.9% originating from EUCTR).

---

## 7. How Competitors Are Using This Data

ClinicalTrials.gov and related registries are already being operationalized by multiple players in the clinical trial technology space. The use cases cluster into four categories.

### 7.1 Competitive Intelligence & Pipeline Tracking

**Citeline Trialtrove**, **Cortellis Clinical** (Clarivate), and others have built commercial products that systematically harvest data from ClinicalTrials.gov and other registries to deliver:
- Pipeline tracking by indication, mechanism of action, and phase
- Competitor trial design analysis (comparators, endpoints, eligibility)
- Drug benchmarking across active and historical trials
- Business development and licensing intelligence

These are sold as standalone intelligence products. CluePoints' customer base — sponsors and CROs — often already subscribes to these tools separately.

### 7.2 Feasibility & Site Selection

**Dataiku**, **Planisware**, and emerging AI-native platforms query ClinicalTrials.gov data to:
- Identify sites with prior experience in a specific indication
- Rank investigator site performance (enrollment history, dropout rates) from publicly available results data
- Benchmark expected enrollment rates by country and therapeutic area
- Flag competitive trials at overlapping sites that may compete for patients

Planisware has integrated a direct ClinicalTrials.gov link within its PPM platform to surface industry benchmarks without leaving the workflow.

### 7.3 RBQM Case Studies and Protocol Benchmarking

The **ACRO RBQM Working Group** explicitly used ClinicalTrials.gov to select representative trials for real-world RBQM strategy development — selecting protocols, endpoints, eligibility criteria, and visit structures to illustrate how centralized monitoring and QTL frameworks should be designed. This demonstrates that registry data is already being used as a **design reference** in the RBQM domain.

**Medidata** and **Veeva** incorporate historical trial data (aggregated from registries and proprietary platform data) into their feasibility and risk baseline models, though the extent to which public ClinicalTrials.gov data is explicitly used versus proprietary platform data is not always disclosed.

### 7.4 AI Agents and Natural Language Access

Emerging AI agent frameworks (as described by Dataiku for life sciences) are building pipelines that:
- Query the ClinicalTrials.gov API v2.0 at runtime
- Perform semantic search across 20,000+ study protocols
- Summarize the competitive landscape for a given indication automatically
- Feed that context into downstream planning and risk tools

The ClinicalTrials.gov API is free, requires no authentication, and returns structured JSON — lowering the barrier to integration substantially.

---

## 8. Strategic Implications for CluePoints

This section is intentionally left as open questions to seed the product brainstorm:

1. **Protocol Intelligence at Study Setup:** When a sponsor sets up a new study in CluePoints, could we auto-populate or validate study parameters (phase, endpoints, enrollment targets, arm structure) against the ClinicalTrials.gov record? Could we flag discrepancies between the registered protocol and what is configured in the RBQM platform?

2. **Enrollment Benchmarking:** Results data contains actual vs. planned enrollment by arm. Could CluePoints surface how similar past trials actually enrolled versus targets — helping calibrate realistic KRIs and QTLs before a study begins?

3. **Site Intelligence:** Site-level participation history (what studies a site has run, in what indications, with what enrollment outcomes) is partially inferable from ClinicalTrials.gov. Could this feed CluePoints' site risk profiling?

4. **Adverse Event Benchmarking:** Published adverse event rates in completed trials of the same drug or class could anchor expected AE rates, helping distinguish signal from noise in central monitoring.

5. **Competitive Context for Sponsors:** Sponsors using CluePoints are running programs, not just studies. Registry data could surface how a sponsor's trial compares in design complexity, enrollment ambition, or timeline to peers — a differentiated insight available nowhere else in the RBQM stack.

6. **Compliance Monitoring:** For sponsors who manage multiple studies, ClinicalTrials.gov can be used to proactively flag which of their registered trials are approaching results submission deadlines or have stale status fields — reducing regulatory risk.

---

## 9. Summary Reference Card

| Dimension | Key Facts |
|---|---|
| **Operator** | U.S. National Library of Medicine (NLM / NIH) |
| **Scale** | 500,000+ registered studies |
| **API** | v2.0, REST/OpenAPI, free, no authentication |
| **Companion DB** | AACT (daily snapshot, relational, free) |
| **Mandatory for** | FDA ACTs (Phase 2+ drugs/biologics, devices with U.S. sites / IND / IDE); all NIH-funded trials |
| **Not mandatory for** | Phase 1 industry trials (no IND), observational studies (non-NIH), non-FDA/non-NIH foreign trials |
| **Registration deadline** | 21 days after first patient enrolled (ICMJE: before first patient) |
| **Update frequency** | 30 days for changes; 12-month maximum between any updates |
| **Results deadline** | 12 months post primary completion date (up to 36 months for unapproved products) |
| **Industry compliance** | ~73.7% for 12-month results reporting |
| **Data quality** | Reliable for structural/design fields; less reliable for real-time status and dates |
| **Global counterparts** | EUCTR (EU), ISRCTN (global), CTRI (India), ChiCTR (China) — all feed WHO ICTRP |
| **Competitor use cases** | Pipeline intelligence, site selection, enrollment benchmarking, AI-assisted feasibility |

---

## Sources

- [ClinicalTrials.gov – FDAAA 801 & Final Rule](https://clinicaltrials.gov/policy/fdaaa-801-final-rule)
- [42 CFR Part 11 – Final Rule (NIH)](https://grants.nih.gov/policy-and-compliance/policy-topics/clinical-trials/reporting/understanding)
- [Protocol Registration Data Element Definitions](https://clinicaltrials.gov/policy/protocol-definitions)
- [ClinicalTrials.gov API v2.0](https://clinicaltrials.gov/data-api/api)
- [AACT Database – CTTI](https://aact.ctti-clinicaltrials.org/)
- [Trial Reporting in ClinicalTrials.gov — The Final Rule (NEJM)](https://www.nejm.org/doi/full/10.1056/NEJMsr1611785)
- [Compliance with Results Reporting at ClinicalTrials.gov (NEJM)](https://www.nejm.org/doi/full/10.1056/NEJMsa1409364)
- [Sponsor-Level Compliance Analysis 2017–2024](https://publichealth.realclearjournals.org/research-articles/2025/09/sponsor-level-compliance-with-clinicaltrials-gov-reporting-requirements-a-comprehensive-analysis/)
- [Data Quality Assessment of Interventional Trials in Public Databases (JCE 2024)](https://www.jclinepi.com/article/S0895-4356(24)00272-5/fulltext)
- [WHO ICTRP Overview](https://www.who.int/tools/clinical-trials-registry-platform)
- [ICTRP Data Integrity Study (Frontiers in Pharmacology 2023)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1228148/full)
- [EUCTR Results Availability Study (PMC 2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10806997/)
- [Citeline Trialtrove](https://www.citeline.com/en/products-services/clinical/trialtrove)
- [Planisware ClinicalTrials.gov Benchmarking](https://planisware.com/resources/ai-ppm/are-you-leading-or-falling-behind-benchmarking-pharma-success-public-data)
- [Dataiku AI Agents for Life Sciences](https://www.dataiku.com/stories/blog/building-ai-agents-for-life-sciences)
- [RBQM Centralized Monitoring Case Study (Springer 2024)](https://link.springer.com/article/10.1007/s43441-024-00719-1)
- [Comprehensive Assessment of RBQM Adoption (PMC 2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11043178/)
